Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
Nature Reviews: Utilizing the gut microbiome in decompensated cirrhosis and acute- on- chronic liver failure
Read the latest nature reviews article which focuses on the possible pathogenic, diagnostic and therapeutic role of the gut microbiome in decompensation of cirrhosis and progression to ACLF by Jonel Trebicka, Peer Bork, Aleksander Krag and Manimozhiyan Arumugam. Read more.More news
MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021 in Frankfurt
Management of acute-on-chronic liver failure - Course director: Prof. Jonel Trebicka - Location: Goethe University Frankfurt // Date: 01.07.2021More events